BioNTech Results Presentation Deck

BNT311: Phase 1 / 2a - Anti-tumor Activity: Dose escalation Best relative change in SoD from baseline (%) Best percent change from baseline in tumor size 75 50 25 -50 -75 19 PD PD PD PD PD PD PD mg 140 mg 400 mg 1200 mg 50 mg 25 PD PD PD PD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD SD PD SD SD SD SD SD SD SD PD PD SD SD SD NE PR UPRbuPRD PR mg mg 80 mg 140 mg 200 mg 200 mg 800 mg 200 mg 140 mg 400 mg 140 mg 80 mg 140 mg 800 mg 800 mg 200 mg 80 mg 400 mg 50 mg 400 mg 80 mg 25 mg 140 mg 100 mg 200 mg 80 mg 1200 mg 800 mg 100 mg 1200 mg 80 mg 100 mg 400 mg 400 mg 25 Dose level 1200 800 mg 50 mg 50 mg 80 mg 200 mg 400 mg 400 mg Colorectal cancer NSCLC Ovarian cancer Pancreatic cancer Other cancer Prior PD-(L)1 800 mg 50 mg 400 mg Data cut-off: September 29, 2020. Post-baseline scans were not conducted for five patients. aMinimum duration of response (5 weeks) per RECIST v1.1 not reached. bPR was not confirmed on a subsequent scan. NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PR, partial response; SD, stable disease; SoD, sum of diameters; uPR, unconfirmed partial response. 6 : 008 200 mg 800 mg 80 mg 80 mg → Disease control achieved in 65.6% of patients; four patients with PR Includes 4 early partial responses in TNBC (1), ovarian cancer (1), and ICI-pre treated NSCLC (2) patients 200 mg 100 mg BIONTECH 19

View entire presentation